Gene therapy mends wounds in rare 'butterfly skin' disease
NCT ID NCT06892639
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a treatment called D-Fi, made from a person's own skin cells that are genetically modified to produce a missing protein. It aims to see if injecting these cells into wounds helps them close completely compared to standard care alone. The trial includes 32 children and adults with dystrophic epidermolysis bullosa, a condition that causes fragile skin and chronic wounds.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DYSTROPHIC EPIDERMOLYSIS BULLOSA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Children's Hospital Colorado
Aurora, Colorado, 80045, United States
-
Mission Dermatology
Santa Margarita, California, 92688, United States
-
Stanford University School of Medicine, Dermatology
Redwood City, California, 94063, United States
-
University of Massachusetts
Worcester, Massachusetts, 01655, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New hope for blistering skin diseases: drug targets antibodies to heal wounds
- New combo therapy aims to heal wounds in rare skin disease
- New eye drops aim to ease painful corneal scratches in rare skin disease
- New gel could ease pain and heal wounds for kids with butterfly skin
- New eye drops aim to soothe blistering eye pain in rare skin disease
- Could Cell-Derived vesicles heal skin wounds in epidermolysis bullosa?